J&J expects double-digit 2023 profit growth after Kenvue spinoff
Reuters
Published Aug 30, 2023 06:40AM ET
Updated Aug 30, 2023 08:56AM ET
(Reuters) -Johnson & Johnson on Wednesday forecast double-digit profit growth for 2023 after spinning off consumer health company Kenvue (NYSE:KVUE), unveiling the first outlook for its standalone drugs and medical device businesses.
J&J (NYSE:JNJ) finalized the biggest shake-up in its 137-year history earlier this month through an exchange of its shares with Kenvue's, leaving the pharmaceutical giant with a reduced 9.5% stake in its former unit.
Kenvue debuted on the New York Stock Exchange in May and has a market capitalization of nearly $79 billion, with J&J generating $13.2 billion in cash proceeds as a result of its debt offering and initial public offering.
"The main driver for this transaction always has been the strategic rationale of having both companies be more agile, flexible and focused for success in their respective industries," J&J CFO Joseph Wolk said in a pre-recorded investor call.
J&J expects 2023 adjusted reported earnings per share of $10 to $10.10, which is 12.5% higher at the midpoint compared with 2022.
The company also said it would present its consumer health business as discontinued operations and record a gain of $20 billion in the third quarter as a result of the spinoff.
J&J in July expressed optimism for strong growth this year, saying it expected demand for joint replacement and other surgeries to rebound with COVID-19 and inflation tempering.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.